Target Price | $66.55 |
Price | $34.06 |
Potential | 95.39% |
Number of Estimates | 20 |
20 Analysts have issued a price target Moderna 2026 . The average Moderna target price is $66.55. This is 95.39% higher than the current stock price. The highest price target is $212.00 522.43% , the lowest is $27.00 20.73% . | |
A rating was issued by 28 analysts: 8 Analysts recommend Moderna to buy, 16 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Moderna stock has an average upside potential 2026 of 95.39% . Most analysts recommend the Moderna stock at Hold. |
22 Analysts have issued a sales forecast Moderna 2024 . The average Moderna sales estimate is $3.2b . This is 36.17% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $3.7b 28.05% , the lowest is $3.0b 40.53% .
This results in the following potential growth metrics:
2023 | $6.8b | 64.21% |
---|---|---|
2024 | $3.2b | 52.66% |
2025 | $2.7b | 16.21% |
2026 | $3.3b | 22.36% |
2027 | $4.3b | 29.20% |
2028 | $5.6b | 29.89% |
10 Analysts have issued an Moderna EBITDA forecast 2024. The average Moderna EBITDA estimate is $-3.6b . This is 51.98% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $-3.1b 28.82% , the lowest is $-4.0b 68.32% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $-3.6b | 137.72% |
---|---|---|
2024 | $-3.6b | 0.67% |
2025 | $-3.4b | 6.62% |
2026 | $-2.7b | 20.96% |
2027 | $-1.5b | 44.67% |
2023 | -53.01% | 205.37% |
---|---|---|
2024 | -111.23% | 109.82% |
2025 | -123.97% | 11.45% |
2026 | -80.07% | 35.41% |
2027 | -34.29% | 57.17% |
15 Moderna Analysts have issued a net profit forecast 2024. The average Moderna net profit estimate is $-3.6b . This is 61.15% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $-3.1b 40.03% , the lowest is $-4.0b 79.56% .
This results in the following potential growth metrics and future Net Margins:
2023 | $-4.8b | 161.39% |
---|---|---|
2024 | $-3.6b | 24.00% |
2025 | $-3.5b | 1.81% |
2026 | $-2.9b | 18.93% |
2027 | $-2.1b | 26.86% |
2028 | $-1.9b | 10.81% |
2023 | -69.46% | 271.51% |
---|---|---|
2024 | -111.51% | 60.54% |
2025 | -130.68% | 17.19% |
2026 | -86.57% | 33.75% |
2027 | -49.01% | 43.39% |
2028 | -33.65% | 31.34% |
15 Analysts have issued a Moderna forecast for earnings per share. The average Moderna <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $-9.38 . This is 61.17% lower than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $-8.15 40.03% , the lowest is $-10.45 79.55% .
This results in the following potential growth metrics and future valuations:
2023 | $-12.34 | 161.39% |
---|---|---|
2024 | $-9.38 | 23.99% |
2025 | $-9.21 | 1.81% |
2026 | $-7.47 | 18.89% |
2027 | $-5.46 | 26.91% |
2028 | $-4.87 | 10.81% |
Current | -5.85 | 45.22% |
---|---|---|
2024 | -3.63 | 37.95% |
2025 | -3.70 | 1.93% |
2026 | -4.56 | 23.24% |
2027 | -6.24 | 36.84% |
2028 | -6.99 | 12.02% |
Based on analysts' sales estimates for 2024, the Moderna stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 2.35 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 4.05 .
This results in the following potential growth metrics and future valuations:
Current | 1.50 | 57.39% |
---|---|---|
2024 | 2.35 | 56.36% |
2025 | 2.80 | 19.35% |
2026 | 2.29 | 18.28% |
2027 | 1.77 | 22.60% |
2028 | 1.36 | 23.01% |
Current | 2.58 | 38.36% |
---|---|---|
2024 | 4.05 | 56.66% |
2025 | 4.83 | 19.35% |
2026 | 3.95 | 18.28% |
2027 | 3.06 | 22.60% |
2028 | 2.35 | 23.02% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.